Technology | Catheters | July 13, 2016

VentureMed Group Announce FDA Approval of FLEX Scoring Catheter

Surgical device provides alternative to balloon-based scoring for endovascular treatment of peripheral arterial disease

VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment

July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of peripheral arterial disease (PAD), announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Flex Scoring Catheter.

The catheter is an endovascular surgical device that precisely and dynamically scores any length atherosclerotic lesion as it passes through the femoral-popliteal anatomy. Flex provides an alternative to balloon-based scoring with a one-size-fits-all platform technology. 

VentureMed Group founder and chief science officer John Pigott, M.D., said the first-in-man trial of the device showed statistically significant improvement in ankle-brachial index scores at 30 days.  

FDA clearance of Flex, which received CE Mark in Europe in 2015, will provide interventionalists with a vessel preparation device that allows for effective dynamic linear scoring with a lower propensity for barotrauma or vessel wall damage. The design allows the operator to easily prepare a diseased vessel in a single insertion without the need for multiple balloon inflations.

The catheter is inserted over an 0.018-inch guidewire (6F compatible sheath) and threaded through the patient’s artery to a point just below the blockage. The surgeon pulls a thumb lever that exposes three precision atherotomes that are radially mounted at the tip of the catheter. As the catheter is drawn through the lesion, the blades make continuous micro-scores, relaxing the plaque. Next, the balloon is inflated to achieve luminal gain, allowing blood to flow freely.

For more information: www.venturemedgroup.com

Related Content

Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is a walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Overlay Init